NL300391I2 - Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin - Google Patents

Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Info

Publication number
NL300391I2
NL300391I2 NL300391C NL300391C NL300391I2 NL 300391 I2 NL300391 I2 NL 300391I2 NL 300391 C NL300391 C NL 300391C NL 300391 C NL300391 C NL 300391C NL 300391 I2 NL300391 I2 NL 300391I2
Authority
NL
Netherlands
Prior art keywords
japanese encephalitis
weakened
vero cells
vaccine
virus adapted
Prior art date
Application number
NL300391C
Other languages
English (en)
Dutch (nl)
Other versions
NL300391I1 (nl
Original Assignee
Cheil Jedang Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp, Us Army filed Critical Cheil Jedang Corp
Publication of NL300391I1 publication Critical patent/NL300391I1/nl
Publication of NL300391I2 publication Critical patent/NL300391I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300391C 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin NL300391I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
NL300391I1 NL300391I1 (nl) 2009-08-03
NL300391I2 true NL300391I2 (nl) 2009-11-02

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300391C NL300391I2 (nl) 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Country Status (15)

Country Link
US (1) US6309650B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1025209B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4161017B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100314404B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1142271C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU748730B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2301000C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122009000037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1604685T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2382946T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY129773A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300391I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ503522A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1999011762A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
CN1618464A (zh) 1998-10-05 2005-05-25 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
MXPA01010681A (es) * 1999-04-22 2003-08-20 Us Agriculture Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
EP2233151B1 (en) * 2007-12-26 2016-05-11 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Method of producing japanese encephalitis virus vaccine stably storable over long time and use of the vaccine
JP5511660B2 (ja) 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
ES2930458T3 (es) 2011-12-06 2022-12-13 Valneva Austria Gmbh Compuestos de aluminio para su uso en agentes terapéuticos y vacunas
AU2014338520B2 (en) * 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
WO2017109225A1 (en) 2015-12-23 2017-06-29 Valneva Austria Gmbh Zika virus vaccine
WO2017122635A1 (ja) * 2016-01-15 2017-07-20 一般財団法人化学及血清療法研究所 固定化ウイルス粒子を含むワクチン
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
AU2018337681B2 (en) 2017-09-21 2025-04-10 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus chikv-delta5nsp3
EP3703739A2 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN116983399A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
JP7376013B2 (ja) * 2018-08-27 2023-11-08 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
EP4114463A4 (en) 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A1 (en) * 2022-04-20 2024-09-11 Korea National Institute of Health High-titer japanese encephalitis virus genotype 5 and use thereof
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
US6309650B1 (en) 2001-10-30
MY129773A (en) 2007-04-30
ES2382946T3 (es) 2012-06-14
EP1604685B1 (en) 2012-02-22
DK1025209T3 (da) 2007-06-25
AU748730B2 (en) 2002-06-13
DE122009000037I2 (de) 2011-06-16
FR09C0037I2 (fr) 2021-11-05
KR100314404B1 (ko) 2002-10-12
CN1142271C (zh) 2004-03-17
WO1999011762A1 (en) 1999-03-11
EP1025209B1 (en) 2007-02-28
EP1604685A2 (en) 2005-12-14
DE69837211D1 (de) 2007-04-12
ES2281929T3 (es) 2007-10-01
FR09C0037I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-09-25
JP2001514844A (ja) 2001-09-18
KR19990023955A (ko) 1999-03-25
DE69837211T2 (de) 2007-12-06
DE122009000037I1 (de) 2009-11-05
CA2301000A1 (en) 1999-03-11
CA2301000C (en) 2003-07-08
EP1025209A1 (en) 2000-08-09
CN1272879A (zh) 2000-11-08
NL300391I1 (nl) 2009-08-03
EP1604685A3 (en) 2006-07-05
NZ503522A (en) 2001-06-29
DK1604685T3 (da) 2012-06-18
AU9004798A (en) 1999-03-22
JP4161017B2 (ja) 2008-10-08

Similar Documents

Publication Publication Date Title
NL300391I2 (nl) Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin
DK0870508T3 (da) Influenzavaccine
PT810877E (pt) Vacina da hepatite b
CY2012033I2 (el) Φαρμακευτικα σκευασματα σε μορφη αερολυματος
DE69630044D1 (de) Viren inaktivierende umhüllungen
NL300379I1 (nl) Bepaalde 5-alkyl-2- arylaminofenylazijnzuren en derivaten daarvan
NO976060D0 (no) Vaksiner mot hepatitt C
ID28298A (id) Komposisi yang mengandung virus dan metode untuk memekatkan preparat-preparat virus
ID22873A (id) Senyawa-senyawa heterosiklik dan pemakaiannya untuk menginhibisi b-amyloid peptida
IS5433A (is) Sýklískar amínafleiður og notkun þeirra sem lyf
GB9811433D0 (en) Virus vaccine
IT1317988B1 (it) Procedimento e dispositivo per produrre depressione in un veicolo
EP1037974A4 (en) TRUNCATED PROTEIN OF HEPATITIS C VIRUS NS5B AND RELATED METHODS OF IDENTIFYING ANTIVIRAL COMPOUNDS
EP0975363A4 (en) Attenuated respiratory syncytial virus
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
ATE277631T1 (de) Neospora impstoff
GB9713979D0 (en) Method for attaching peg to macromolecules
ATE262324T1 (de) Verkapslung einer untereinheit des bovinen herpes virus typ-1 in wässrigen lösungsmitteln als impfstoff.
EP0769952A4 (en) VACCINE AGAINST THE INFECTIOUS CHICKEN ANEMIA VIRUS
ID28381A (id) Vankoresmisin, suatu proses untuk memproduksinya dan penggunaanya sebagai obat-obatan
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
HU9702540D0 (en) Carrying matherial for virus vaccine administered in intranasal way and virus vaccine itself
KR950010595U (ko) 절첩 및 착탈식 통발
HU0400424D0 (en) Hepatitis virus vaccines
DE60024406D1 (de) Fischsosse und Verfahren zu deren Herstellung